Dina Esposito, NP
Oncology · West Orange, NJNPI 1164935466
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $555 of the $620 with a category attached, or 89.5%. It is spread thinly across 12 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 18 payments — averaging $34.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$120
- Johnson & Johnson$120
- Novartis$88
- Incyte Corporation$88
- Merck$48
- Boston Scientific$32
- plus $123 from 6 others
What the payments were for
- Food & beverage$55590%
- Education$6510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 1 | $120 |
| Johnson & Johnson | 1 | $120 |
| Novartis | 5 | $88 |
| Incyte Corporation | 2 | $88 |
| Merck | 2 | $48 |
| Boston Scientific | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Bristol Myers Squibb | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Genmab U.S., Inc. | 1 | $18 |
| Seagen Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$620 in reported general payments places this provider in the 60th percentile of 23 oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 14 | $187,470 |
| Posaconazole | 13 | $37,830 |
| Ondansetron OdtOndansetron | 67 | $801 |
| Prochlorperazine Maleate | 57 | $426 |
| Dexamethasone | 42 | $378 |
| Prednisone | 99 | $334 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $237 |
| Potassium Chloride | 11 | $65 |
Paid to pharmacies, not to this prescriber.
Other oncology in West Orange
- Ann McNeillNeptune$372K
- Susan WilsonMarmora$10K
- Carol BlecherElizabeth$6K
- Wendy VogelLawrenceville$3K
- Deborah SmithRiverdale$2K
- Michelyne GavinCliffside Park$2K
- Amber DelecceSewell$1K
- Jacquelynn WhiteCamden$908
- Mary KellyBerkeley Heights$799
- Carol BoyerBerkeley Heights$482
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.